Shanghai Junshi Biosciences Co., Ltd.
688180
Peringkat dalam Saham
#3910
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise... Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise dedicated to the research, development, and marketing of innovative therapeutic agents. Operating within the People's Republic of China, their focus spans critical medical areas such as oncology, metabolic diseases, autoimmune disorders, neurological conditions, and infectious diseases. Among its principal offerings is JS001, commercialized as TUOYI. This recombinant humanized anti-PD-1 monoclonal antibody has received approval for a broad spectrum of cancer indications, including various forms of melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. Beyond TUOYI, Junshi Biosciences boasts a robust pipeline of investigational drugs. These include UBP1211, a biosimilar of Humira, targeting conditions like rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody aimed at hyperlipidemia; and UBP1213, a recombinant humanized anti-BLyS monoclonal antibody in injectable form. Further developments encompass JS501, a biosimilar to Avastin; JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, identified as a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. The company has also established strategic collaborations. Notably, it partners with Eli Lilly and Company on the co-development of therapeutic antibodies intended for the prevention and treatment of COVID-19, the illness caused by the SARS-CoV-2 novel coronavirus. Additionally, an alliance with Coherus Biosciences, Inc. facilitates the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Founded in 2012, Shanghai Junshi Biosciences Co., Ltd. maintains its corporate headquarters in Shanghai, People's Republic of China.
Harga Saham
$4.54
Kapitalisasi Pasar
$4.16B
Perubahan (1 hari)
-2.35%
Perubahan (1 tahun)
-16.02%
Negara
CN
Perdagangan Shanghai Junshi Biosciences Co., Ltd. (688180)
Kategori
Healthcare
Rasio P/E untuk Shanghai Junshi Biosciences Co., Ltd. (688180)
Rasio P/E per October 2026 TTM: -70.73
Menurut laporan keuangan dan harga saham terbaru dari Shanghai Junshi Biosciences Co., Ltd., rasio P/E saat ini (TTM) adalah -70.73. Pada akhir 2024, perusahaan memiliki rasio P/E sebesar -21.02.
Riwayat rasio P/E untuk Shanghai Junshi Biosciences Co., Ltd. dari 2014 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | -70.73 | 80.16% |
| 2025 | -39.26 | 86.77% |
| 2024 | -21.02 | 16.60% |
| 2023 | -18.03 | -25.09% |
| 2022 | -24.07 | -70.89% |
| 2021 | -82.69 | 106.98% |
| 2020 | -39.95 | -74.60% |
| 2019 | -157.29 | 24.00% |
| 2018 | -126.85 | -53.52% |
| 2017 | -272.92 | -53.64% |
| 2016 | -588.73 | 1.37% |
| 2015 | -580.77 | -54.81% |
| 2014 | -1.29K | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| 28.78 | -140.69% |
US
|
|
| -28.36 | -59.91% |
US
|
|
| -25.99 | -63.25% |
AU
|
|
| 31.22 | -144.13% |
NL
|
|
| 17.49 | -124.73% |
BE
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.